Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Cancer Treatment Clinical Trials

A listing of Cancer Treatment medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (80) clinical trials

Seeking subjects for a research study using high intensity focused ultrasound (HIFU) to treat prostate cancer that has come back after external beam radiation therapy. Subjects enrolled in this study will receive a onetime treatment (outpatient procedure) with HIFU. After treatment you will be asked to come back to the ...

Phase

If you have had prostate cancer surgery or radiation and your PSA levels are increasing, you may be able to participate in a research study. This study is comparing an investigational medication to an approved treatment method for men who are candidates for hormone suppression therapy. The purpose of the ...

Phase N/A

The MR-guided ExAblate Focused Ultrasound study is being conducted to assess the safety and effectiveness of an investigational device for the treatment of prostate cancer. The ExAblate treatment is a focal treatment where a small portion of the prostate is treated, only where the cancer is located. The study will ...

Phase N/A

The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy results in an improvement of metastasis-free survival. The study will include a Screening Phase, Treatment Phase, a Posttreatment Phase, and ...

Phase

Focal ExAblate MR-Guided Focused Ultrasound Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer

This study will evaluate the proportion of patients with organ-confined intermediate risk prostate cancer (OC-IRPC) undergoing focal ExAblate MRgFUS prostate treatment that will be free of clinically significant PCa which requires definitive treatment at 2 years after completion of their ExAblate treatment and to demonstrate the safety of focal ExAblate ...

Phase N/A

Evaluation and Predictive Value of Genetic Polymorphisms in the Management of Hormonal Treatment of Prostate Cancer

Prostate cancer patients for which reimbursed ADT with a gonadoliberin antagonist is indicated, for a period of at least 6 months will lbe enrolled. At 0, 3 months and 6 months of ADT, Aging Males' Symptoms (AMS), EQ-5D (EuroQoL), and hot flashes intensity and frequency (Moyad scale) will be collected, ...

Phase N/A

Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs miRNAs and Treatment Response

The primary aim is to show whether a reduction in tumor related mRNAs and a panel of selected miRNAS can be used to personalize enzalutamide therapy. Furthermore the aim is to explore the relation between drug exposure and the decrease in the selected biomarkers and treatment response.

Phase N/A

Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer

Patients with metastatic germ cell cancer and relapse after two or more courses of cisplatin-based chemotherapy or after high-dose chemotherapy have a poor prognosis and no curative options. Taxanes in various combinations unfold cytotoxic effects on germ cell tumors resistant to conventional doses of cisplatin. Paclitaxel in combination with ifosfamide ...

Phase

Engaging Newly Diagnosed Men About Cancer Treatment Options

This research is being done to better understand how a new lab test called the Oncotype DX Prostate Cancer Assay may impact what treatment men decide to get and how they feel and think about their choice of treatment. The study will compare men who receive this new lab test ...

Phase N/A

NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma

This is a Phase 1/2 prospective, open-label, two cohorts, non-randomized trial consisting of two consecutive steps, a dose escalation and a subsequent dose expansion part. PART 1 DOSE ESCALATION: subjects with newly diagnosed Unfavorable Intermediate Risk (UIR) or High Risk (HR) prostate adenocarcinoma, will participate in a dose escalation of ...

Phase